Summary
Using nested case–control data from the Lifelines COVID-19 cohort, we undertook a validation study of a clinical and genetic model to predict the risk of severe COVID-19 in people with confirmed COVID-19 and in people with confirmed or self-reported COVID-19. The model performed well in terms of discrimination of cases and controls for all ages (area under the receiver operating characteristic curve [AUC] = 0.680 for confirmed COVID-19 and AUC = 0.689 for confirmed and self-reported COVID-19) and in the age group in which the model was developed (50 years and older; AUC = 0.658 for confirmed COVID-19 and AUC= 0.651 for confirmed and self-reported COVID-19). There was no evidence of over- or under-dispersion of risk scores but there was evidence of overall over-estimation of risk in all analyses (all P < 0.0001). In the light of large numbers of people worldwide remaining unvaccinated and continuing uncertainty regarding vaccine efficacy over time and against variants of concern, identification of people at high risk of severe COVID-19 may encourage the uptake of vaccinations (including boosters) and the use of non-pharmaceutical inventions.
Competing Interest Statement
GSD, NMM, and RA are employees of Genetic Technologies Limited. ES is an employees of Phenogen Sciences Inc (a subsidiary of Genetic Technologies Limited). Genetic Technologies Limited had no role in the conceptualization, design, data analysis, decision to publish or preparation of the manuscript. Aspects of this manuscript are covered by Provisional Patent Application AU_2021900392 (pending), Methods of assessing risk of developing a severe response to Coronavirus infection. GSD, NMM and RA are named inventors on the patent application, which is assigned to Genetic Technologies Limited.
Funding Statement
The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen, Groningen University and the Provinces in the North of the Netherlands (Drenthe, Friesland, Groningen). The analyses undertaken in this study were fully funded by Genetic Technologies Limited.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Lifelines protocol has been approved by the Medical Ethical Committee of the University Medical Center Groningen, The Netherlands, under Approval Number 2007/152. All participants provided written informed consent to Lifelines before data collection began. This research was conducted using Lifelines data under Project Number OV20-00101.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵3 Members of the Lifelines Corona Research Initiative are as follows: Marike H. Boezen,a Jochen O. Mierau,b,c H. Lude Franke,d Jackie Dekens,d,e Patrick Deelen,d Pauline Lanting,d Judith M. Vonk,a Ilja Nolte,a Anil P.S. Ori,d,f Annique Claringbould,d Floranne Boulogne,d Marjolein X.L. Dijkema,d Henry H. Wiersma,d Robert Warmerdam,d Soesma A. Jankipersadsing,d Irene van Bloklandd,g
a. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
b. Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
c. Aletta Jacobs School of Public Health, Groningen, The Netherlands
d. Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
e. Center of Development and Innovation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
f. Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
g. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Data Availability
The data used in this study was made available to us by Lifelines and is not publicly available. Researchers can apply to use the Lifelines data used in this study, and more information about how to request Lifelines data and the conditions of use can be found on their website (https://www.lifelines.nl/researcher/how-to-apply).